About Prokineticin receptor 2
Prokineticin receptor 2 (PROKR2) is a protein
from Homo sapiens identified by UniProt accession
Q8NFJ6, 384 residues long.
MolForge cross-references it against 0 known binders and
189 disease associations.
Target properties
| Protein name | Prokineticin receptor 2 |
| UniProt accession | Q8NFJ6 |
| Gene | PROKR2 |
| Organism | Homo sapiens |
| Length | 384 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (189)
Diseases linked to this target (Open Targets).
- hypogonadotropic hypogonadism 3 with or without anosmia · score 0.82
- Kallmann syndrome · score 0.69
- hypogonadotropic hypogonadism · score 0.44
- male infertility with azoospermia or oligozoospermia due to single gene mutation · score 0.43
- Hirschsprung disease · score 0.37
- Septo-optic dysplasia · score 0.37
- hypogonadotropic hypogonadism 2 with or without anosmia · score 0.34
- genetic disorder · score 0.33
- Male infertility with spermatogenesis disorder · score 0.27
- glioblastoma multiforme · score 0.26
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8NFJ6-F1 | alphafold | PREDICTED | 78.33 | — |
Amino-acid sequence (384 residues)
MAAQNGNTSF TPNFNPPQDH ASSLSFNFSY GDYDLPMDED EDMTKTRTFF AAKIVIGIAL AGIMLVCGIG NFVFIAALTR YKKLRNLTNL LIANLAISDF LVAIICCPFE MDYYVVRQLS WEHGHVLCAS VNYLRTVSLY VSTNALLAIA IDRYLAIVHP LKPRMNYQTA SFLIALVWMV SILIAIPSAY FATETVLFIV KSQEKIFCGQ IWPVDQQLYY KSYFLFIFGV EFVGPVVTMT LCYARISREL WFKAVPGFQT EQIRKRLRCR RKTVLVLMCI LTAYVLCWAP FYGFTIVRDF FPTVFVKEKH YLTAFYVVEC IAMSNSMINT VCFVTVKNNT MKYFKKMMLL HWRPSQRGSK SSADLDLRTN GVPTTEEVDC IRLK
Explore Prokineticin receptor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets